20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Ideaya Biosciences Inc (IDYA) operates in the BIOTECHNOLOGY industry and is headquartered in South San Francisco, United States with about 145 employees. Its market capitalization is roughly $4 billion. In the fiscal year ended 2025-12-31, IDYA reported $219M in revenue and ($114M) in net income.
IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States.
Interactive charts & full statements → Open the IDYA valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $234M | $219M | $7M | $23M | $51M | $28M | $20M | $0M | $0M | $0M |
| Gross Profit | ($31M) | ($96M) | $3M | $19M | $51M | $28M | $20M | ($1M) | ($1M) | $0M |
| Gross Margin % | -13.3% | -43.9% | 45.2% | 82.9% | 100.0% | 100.0% | 100.0% | — | — | — |
| Operating Income (EBIT) | ($217M) | ($159M) | ($327M) | ($134M) | ($63M) | ($50M) | ($35M) | ($44M) | ($36M) | ($14M) |
| Operating Margin % | -92.7% | -72.8% | -4671.1% | -574.9% | -122.7% | -179.9% | -180.9% | — | — | — |
| Net Income | ($175M) | ($114M) | ($274M) | ($113M) | ($55M) | ($48M) | ($32M) | ($38M) | ($34M) | ($12M) |
| Net Margin % | -74.8% | -52.0% | -3921.1% | -483.0% | -107.6% | -170.1% | -165.1% | — | — | — |
| EBITDA | ($212M) | ($155M) | ($271M) | ($109M) | ($60M) | ($49M) | ($34M) | ($43M) | ($33M) | ($11M) |
| Earnings Per Share (EPS) | $-1.94 | $-1.28 | $-3.36 | $-1.96 | $-1.32 | $-1.35 | $-1.31 | $-1.90 | $-2.41 | $-0.83 |
| Shares Outstanding (M) | 92M | 88M | 82M | 58M | 41M | 35M | 25M | 20M | 14M | 14M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $9M | $7M | $11M | $208M | $0M | $0M | $7M | $0M |
| Gross Profit | $9M | ($89M) | ($76M) | $125M | ($74M) | ($71M) | $6M | ($1M) |
| Gross Margin % | 100.0% | -1359.2% | -696.2% | 60.1% | — | — | 90.8% | — |
| Operating Income (EBIT) | ($122M) | ($109M) | ($95M) | $108M | ($89M) | ($84M) | ($144M) | ($67M) |
| Operating Margin % | -1380.7% | -1654.6% | -869.5% | 52.2% | — | — | -2059.1% | — |
| Net Income | ($112M) | ($99M) | ($83M) | $119M | ($77M) | ($72M) | ($130M) | ($52M) |
| Net Margin % | -1269.6% | -1502.1% | -765.7% | 57.4% | — | — | -1861.6% | — |
| EBITDA | ($121M) | ($107M) | ($93M) | $109M | ($88M) | ($83M) | ($130M) | ($51M) |
| Earnings Per Share (EPS) | $-1.22 | $-1.11 | $-0.94 | $1.33 | $-0.88 | $-0.82 | $-1.49 | $-0.60 |
| Shares Outstanding (M) | 92M | 89M | 89M | 90M | 88M | 88M | 87M | 86M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($187M) | ($71M) | ($248M) | ($115M) | ($87M) | ($56M) | $55M | ($39M) | ($28M) | ($12M) |
| Capital Expenditures (CapEx) | $3M | $2M | $4M | $2M | $3M | $3M | $0M | $1M | $2M | $2M |
| Free Cash Flow (FCF) | ($190M) | ($73M) | ($251M) | ($118M) | ($91M) | ($58M) | $55M | ($41M) | ($29M) | ($14M) |
| FCF Margin % | -81.2% | -33.6% | -3592.0% | -502.9% | -177.9% | -209.1% | 281.3% | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($163M) | ($75M) | ($90M) | $142M | ($62M) | ($60M) | ($122M) | ($49M) |
| Capital Expenditures (CapEx) | $2M | $1M | $0M | $0M | $1M | $1M | $1M | $0M |
| Free Cash Flow (FCF) | ($165M) | ($76M) | ($91M) | $142M | ($63M) | ($62M) | ($123M) | ($50M) |
| FCF Margin % | -1865.4% | -1160.6% | -835.1% | 68.4% | — | — | -1753.7% | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.3B | $1.1B | $1.1B | $649M | $388M | $381M | $298M | $113M | $97M | $17M |
| Cash & Cash Equivalents | $273M | $113M | $84M | $157M | $69M | $92M | $72M | $34M | $21M | $6M |
| Total Liabilities | $111M | $86M | $65M | $28M | $39M | $80M | $100M | $13M | $145M | $33M |
| Total Debt (Short + Long-Term) | $1M | $0M | $0M | $2M | $2M | $2M | $2M | $1M | $0M | $3M |
| Total Shareholders' Equity | $1.2B | $1.0B | $1.1B | $621M | $349M | $302M | $198M | $100M | ($49M) | ($16M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive IDYA viewer.
About TickerBase · Data methodology & sources · Privacy · Terms